Video
Peter Koshland, PharmD, CEO of Koshland Pharm and a practicing pharmacist, discusses how compounding pharmacies manage quality assurance when putting together ketamine dosages for patients.
Pharmacy Times interviewed Peter Koshland, PharmD, CEO of Koshland Pharm and a practicing pharmacist, on the current role of the pharmacist in ketamine therapy. Koshland’s compounding pharmacy is based in San Francisco and has worked in the ketamine therapy space since the FDA approval of the drug.
During the discussion, Koshland addresses the specific type of ketamine therapy provided by compounding pharmacies, the prescribing structure for sublingual ketamine therapy, and how compounding pharmacies manage quality assurance when putting together ketamine dosages for patients with a sublingual ketamine prescription from a provider.